Physician profile
Todd D Mishima
NPI 1841215365
$2,186.76
in general payments reported to CMS, 2019-2025
14 companies · $39.91 in 2025
The $39.91 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $127 · 2021: $197 · 2022: $518 · 2023: $262 · 2024: $426 · 2025: $39.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $426.97 | 2019-2023 | |
| Allergan, INC. | $334.60 | 2019-2022 | |
| Oyster Point Pharma, INC. | $289.50 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $276.61 | 2022-2024 | Rocklatan |
| Bausch & Lomb Americas INC. | $194.71 | 2023-2025 | Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $138.16 | 2021-2022 | |
| Shire North American Group INC | $123.51 | 2019 | |
| Abbvie INC. | $102.90 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $68.58 | 2019 | |
| Eyevance Pharmaceuticals LLC | $59.89 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $55.34 | 2019-2021 | |
| Thea Pharma INC. | $47.15 | 2022-2023 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.46 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $28.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Mishima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.